There are currently 50 clinical trials in Virginia Beach, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Urology of Virginia, Urology of Virginia, PLLC, Pfizer Investigational Site and Tidewater Integrated Medical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CCT-102 vs. Expectant Management in Delayed Pregnancy Loss
NCT06121063
Recruiting
A Phase 3, multi-center clinical trial of a CCT-102 regimen compared to expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
02/14/2024
Locations: Tidewater Clinical Research, Virginia Beach, Virginia
Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss
Register for Updates
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
NCT03104517
Recruiting
This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in adult female patients with post-surgical persistent or recurrent stress urinary incontinence (SUI). Half of the participants will receive AMDC-USR (injections with cells) and the other half will receive placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Urology of Virginia, PLLC, Virginia Beach, Virginia
Conditions: Stress Urinary Incontinence
Register for Updates
An Internet-based Program to Help Cancer Survivors Manage Pain
NCT04462302
Recruiting
To determine whether an Internet-based pain coping skills program plus enhanced usual care, compared to enhanced usual care alone, yields significant improvements in the co-primary outcomes of pain severity (as measured by the Brief Pain Inventory (BPI)) and pain interference (also measured by the BPI) from baseline to the post-intervention assessment for cancer survivors with persistent pain.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Peninsula Cancer Institute - Cancer Specialists of Tidewater, Virginia Beach, Virginia
Conditions: Cancer
Register for Updates
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Virginia Beach, Virginia
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Peninsula Cancer Institute-Cancer Specialists of Tidewater, Virginia Beach, Virginia
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
ProVee Urethral Expander System IDE Study (ProVIDE)
NCT05186740
Recruiting
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH).
Gender:
Male
Ages:
45 years and above
Trial Updated:
01/24/2024
Locations: Urology of Virginia, Virginia Beach, Virginia
Conditions: Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms
Register for Updates
Aerofit Post Market Investigation
NCT05925712
Recruiting
The goal of this clinical investigation is to evaluate the clinical benefits of a ventilating suspension interface for individuals with transfemoral amputation. The main aim of the investigation will be to evaluate the clinical user-reported benefits to skin health from using a ventilating lower limb prosthetic suspension system and compare it to a non-ventilating suspension system.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Reach Orthotics and Prosthetics Services, Virginia Beach, Virginia
Conditions: Transfemoral Amputation, Amputation, Skin Health
Register for Updates
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756
Recruiting
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Peninsula Cancer Institute-Cancer Specialists of Tidewater, Virginia Beach, Virginia
Conditions: Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Register for Updates
Total Shoulder Arthroplasty Multi-Center Registry
NCT03511586
Recruiting
The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/27/2023
Locations: Not set, Virginia Beach, Virginia
Conditions: Shoulder Arthroplasty
Register for Updates
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT03233191
Recruiting
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Gender:
Female
Ages:
Between 45 years and 74 years
Trial Updated:
06/21/2023
Locations: Sentara Princess Anne Hospital, Virginia Beach, Virginia
Conditions: Breast Screening
Register for Updates
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Urology of Virginia, Virginia Beach, Virginia
Conditions: Bladder Cancer
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Sentara Neurology Specialists, Virginia Beach, Virginia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates